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ABSTRACT 
Background: Walking abnormalities in people with Parkinson’s disease (PD) are characterized 
by a shift in locomotor control from healthy automaticity to compensatory prefrontal executive 
control. Indirect measures of automaticity of walking (e.g., step-to-step variability and dual-task 
cost) suggest that freezing of gait (FoG) may be associated with reduced automaticity of 
walking. However, the influence of FoG status on actual prefrontal cortex (PFC) activity during 
walking remains unclear. Objective: To investigate the influence of FoG status on automaticity 
of walking in people with PD. Methods: Forty-seven people with PD were distributed into two 
groups based on FoG status, which was assessed by the New Freezing of Gait Questionnaire: 
PD-FoG (n=23; UPDRS-III=35) and PD+FoG (n=24; UPDRS-III=43.1). Participants walked 
over a 9m straight path (with a 180° turn at each end) for 80s. Two conditions were tested Off 
medication: single- and dual-task walking (i.e., with a concomitant cognitive task). A portable 
functional near-infrared spectroscopy system recorded PFC activity while walking (including 
turns). Wearable inertial sensors were used to calculate spatiotemporal gait parameters. Results: 
PD+FoG had greater PFC activation during both single and dual-task walking than PD-FoG 
(p=0.031). There were no differences in gait between PD-FoG and PD+FoG. Both groups 
decreased gait speed (p=0.029) and stride length (p<0.001) during dual-task walking compared 
to single-task walking. Conclusions: These findings suggest that PD+FoG have reduced 
automaticity of walking, even in absence of FoG episodes. PFC activity while walking seems to 
be more sensitive than gait measures in identifying reduction in automaticity of walking in 
PD+FoG. 
Keywords: Locomotion, fNIRS, dual-tasking  
INTRODUCTION 
Freezing of gait (FoG) is one of the most debilitating walking impairment in Parkinson’s 
disease (PD). FoG is defined as a “brief, episodic absence or marked reduction of forward 
progression of the feet despite the intention to walk”.1 It occurs in up to 63% of individuals with 
PD, with increasing frequency in more advanced stages of the disease.2,3. FoG episodes often 
result in falls, disability, reduced functional independence and poor quality of life.1,4,5 FoG is 
often difficult to treat1,6 and the development of enhanced interventions requires a better 
understanding of the neural basis of FoG.  
Although the underlying pathophysiology of FoG is not fully understood,7 it is thought to 
be associated with reduced automaticity in the control of walking.8-10 A hallmark of healthy 
walking is automaticity, defined as the ability of the nervous system to successfully control 
movement with minimal use of executive-attentional resources.11 It has been proposed that many 
walking abnormalities in people with PD are characterized by a shift in locomotor control from 
healthy automaticity to compensatory prefrontal executive control.12-17 Behavioral studies 
demonstrate that people with FoG have increased gait variability (i.e., surrogate measure of gait 
automaticity where higher variability equates to reduced automaticity) compared to people 
without FoG. In addition, gait impairments, such as reduced gait speed, are more pronounced in 
people with FoG when walking during dual-task conditions compared to people without 
FoG.8,16,18,19 These behavioral findings suggest that automaticity of walking is poorer in PD with 
FoG compared to PD without FoG. However, these are indirect measures of automaticity of 
walking and, therefore, more direct neurophysiological measures are needed for a better 
understanding of the control mechanisms of walking in people with FoG. 
Neuroimaging studies suggest that two distinct supraspinal locomotor networks are 
involved in the control of walking.20-22 The automatic locomotor network is mainly active during 
steady state walking and it involves direct projections from the primary motor cortex to the 
central pattern generator circuits.20,21 The executive locomotor network is active for complex 
walking requiring planning and modulation of locomotion.20-22 In the executive network, 
locomotor signals originate in the supplementary motor area and the prefrontal cortex (PFC) and 
are transmitted through the basal ganglia (i.e., striatum, pallidum and subthalamic and 
mesencephalic locomotor region) before reaching the medullary and pontine reticular formations 
and the spinal cord.20,21 A feedback loop runs from the spinal cord to the cerebellum and thereby 
via the thalamus to the cortex in both networks.20,21  In PD, the executive locomotor network is 
activated as a compensatory mechanism even during single-task walking.21,22 Using this model 
as a background framework, direct measures of automaticity and executive control can be 
obtained by recording cortical activity during actual walking. For example, functional near-
infrared spectroscopy (fNIRS) systems can be used to record changes in cortical oxy- (HbO2) 
and deoxygenated hemoglobin (HHb) concentrations, which infer cortical activity.  
Measures of PFC activity obtained using fNIRS are reliable23 and can differentiate 
healthy older adults and clinical populations, such as people with PD.13,23,24 Existing studies 
focusing on FoG mainly characterize the executive control of turning.25-27 People with PD with 
FoG have increased PFC activity while turning in place in comparison to non-freezers.26 
Increased PFC activity has also been reported immediately before and during FoG episodes 
when turning 180° during walking.27 In addition, higher PFC activity while turning in place is 
associated with worse FoG severity and poorer turning performance.26 Such findings suggest 
greater prefrontal executive control of turning in people with FoG. However, the influence of 
FoG status on automaticity of walking is still unclear. Based on evidence from gait studies and 
the increased PFC activity reported for those with FoG in turning studies, we would expect that 
during walking PFC activity would be greater in people with PD who report FoG compared to 
non-freezers, even in absence of an actual episode of FoG. Such increased PFC activity would 
indicate a reduction in automaticity of walking even in absence of an actual FoG episode, and 
could partly explain the additional gait impairments noticed in people with FoG compared to 
people without FoG with similar disease severity.  
In the current study, we recorded PFC activity and spatiotemporal gait parameters during 
single and dual-task walking to investigate the influence of FoG status on automaticity of 
walking in people with PD. As we hypothesized that people with FoG have reduced automaticity 
of walking in comparison to people without FoG, we expected to observe increased PFC activity 
and step-to-step variability in people with FoG. We also expected greater deterioration of gait 
measures under dual-task walking in people with FoG compared to non-freezers. Additionally, 
this study explored the relationship between PFC activity while walking and spatiotemporal gait 
parameters and FoG severity. 
 
METHODS 
Participants 
Participants were recruited from local Neurology clinics via referrals from movement 
disorder specialist neurologists. Forty-seven people with idiopathic PD were included in the 
study. Participants were included if they were aged 55-90 years, had a diagnosis of idiopathic PD 
according to the UK Brain Bank Criteria, were taking anti-parkinsonian medication, and were 
able to give informed consent to participate, and able to cooperate with the testing. Exclusion 
criteria included: inability to stand or walk for 2 min at a time, factors affecting gait (e.g., 
musculoskeletal disorders, hip replacement, uncorrected vision or vestibular problems, etc.) and 
inability to follow instructions. Participants were grouped according to their perceived FoG 
status, which was assessed by the New Freezing of Gait Questionnaire28 (NFoGQ): freezers 
(NFoGQ ≥ 1; PD+FoG) and non-freezers (NFoGQ = 0; PD-FoG). Study procedures were 
approved by the Oregon Health and Science University Institutional Review Board (eIRB #9903 
and #17805), with written informed consent obtained prior to participation. 
 
Experimental procedures and equipment 
All participants were tested in their ‘‘Off” medication state, at least 12 h after the last 
administration of their usual anti-parkinsonian medications. Participant characteristics of age, 
sex, disease duration, height, and weight were recorded. Disease severity was measured using the 
Movement Disorders Society (MDS-revised) Unified Parkinson’s disease Rating Scale29 (MDS-
UPDRS). PD stage was assessed by the Hoehn and Yahr Rating Scale30 (H&Y). Cognitive 
function was assessed with the following tests: the Montreal Cognitive Assessment31 (MoCA), 
the Frontal Assessment Battery32 (FAB), the Royall Clock Drawing Tasks33 (CLOX 1 and 2), 
and the Trail Making Test (TMT). 
Participants walked, at self-selected comfortable pace, back and forth over a 9m straight 
path, with a 180° turn at each end. Two conditions were tested in a randomized order: single and 
dual-task walking. Each condition included an initial 20 s of quiet standing (baseline period) 
followed by 80 s of walking (task period). Participants performed a single trial for each walking 
condition. The dual-task condition consisted of executing the walking task while performing a 
concurrent cognitive task (auditory Modified AX-Continuous Performance Task),34 which 
required participants to press a handheld button after a two-paired letters sequence. The sequence 
consisted of a cue letter ‘‘A” and a probe letter ‘‘I” presented sequentially so that the target trail 
was ‘‘AI” and participants were asked to respond as fast as possible after the probe letter. No 
information about task priority was assigned to participants not to influence the task execution. A 
research assistant stood by and walked with the participants to avoid eventual falls and ensure 
their safety. The Modified AX-Continuous Performance Task was also applied while participants 
were seated in a chair (before the walking part). No FoG episode occurred during the protocol. 
A portable 8-channel fNIRS system (OctaMon, Artinis Medical Systems, Elst, The 
Netherlands) recorded changes in HbO2 and HHb bilaterally in the PFC at a sampling rate of 50 
Hz. The fNIRS device consisted of two light detectors and eight light emitters (continuous wave 
diodes with wavelengths of 760 and 850 nm). Three regular channels (interoptode distance of 35 
mm) and one short-separation channel (interoptode distance 15 mm) were used for each 
hemisphere. Optodes were placed on participants forehead using a headband with predetermined 
locations (according to the international 10-20 EEG system). A digitizer (Polhemus Patriot 3D 
digitizer, Colchester, VT, USA) was used to provide 3-dimensional coordinates of anatomical 
references (Cz, nasion, inion and left and right preauricular points) and positions of optodes.  
Eight inertial measurement units (Opal, APDM, Portland, OR, USA) were used to 
quantify spatiotemporal gait parameters at a sampling rate of 128 Hz. They were located at the 
sternum and pelvis levels, on the wrists, shanks and both feet of participants. Each inertial sensor 
consisted of tri-axial accelerometers, gyroscopes, and magnetometers, and were securely fixed to 
the participant’s body with Velcro straps. The inertial sensors and fNIRS system were 
synchronized through the Artinis PortaSync.  
 
Data analysis 
Processing of fNIRS signals followed current recommendations.22,35 Data from the 
digitizer was entered into the software package NIRS-SPM 
(http://www.nitrc.org/projects/nirs_spm),36 which was implemented within MATLAB 2017a 
(The Mathworks Inc., Natick, MA, USA). The spatial registration routine was used to find the 
correspondence between the scalp location where the fNIRS measurement was performed and its 
underlying cortical surface where the source signal was located.37 Cortical regions assessed 
included the Brodmann areas 9 and 10.  
The fNIRS data were preprocessed within custom-made MATLAB algorithms, which 
consisted of several steps. The initial steps involved functions available in HOMER2 
(https://homer-fnirs.org/), and specifically: 1) raw intensity data were converted into optical 
density, 2) artifacts were removed/attenuated by wavelet filtering;38 3) optical density data were 
converted into HbO2 and HHb concentrations; 4) remaining artifacts were removed/attenuated by 
applying the correlation-based signal improvement method.39 The data were then baseline 
corrected by subtracting the mean of the baseline period (standing) from the entire trial. The 
following step involved removing superficial hemodynamic response from regular channels.23,40 
Briefly, scaling factors were determined by detecting the peaks (positive and negative) of the 
heart rate within the regular and short-separation channel signals, then dividing them to produce 
the scaling factors for each pair of channels. These were then used to remove the noise detected 
within the short-separation reference channels within the regular channels. A low-pass filter with 
a cut-off frequency of 0.14 Hz removed any remaining high-frequency noise and the six channels 
were median averaged. Finally, relative changes in HbO2 and HHb concentrations were 
calculated for both early (median of the first half of the task = initial 40 s) and late (median of the 
second half of the task = final 40 s) phases of the task, considering straight walk and turns 
together. The division of the fNIRS signal into early and late phases was motivated by previous 
studies showing phase-specific PFC activation patterns while walking.35,41-43 
Spatiotemporal gait measures were calculated from the inertial sensors using the Mobility 
Lab software, V2 (APDM, Portland, OR, USA).44 All recorded steps corresponding to walking 
were included in the analysis. The following gait measures were calculated: gait speed, stride 
length, foot strike angle and step time variability (coefficient of variation). The accuracy of the 
Modified AX-Continuous Performance Task was calculated for both seated and walking (i.e., 
dual-task walking) conditions. 
 
Statistical Analysis 
Independent t-tests and Mann-Whitney tests were used to compare demographic and 
clinical/cognitive variables between groups. Linear mixed-effects models were fit, using the 
Restricted Maximum Likelihood Estimation (REML), to investigate whether outcomes differed 
between groups and conditions, while controlling (model #2) or not (model #1) for between-
group differences on demographic and clinical/cognitive variables (i.e., MDS-UPDRS-III, H&Y, 
disease duration, MoCA and TMT-B). The use of covariates in the model allowed us to better 
isolate the factor of interest (i.e., FoG status) in the analysis. Moreover, comparison between 
results of the two models would provide evidence on whether or not the covariates influence 
potential changes on PFC activity and gait in PD-FoG and PD+FoG. REML estimation were 
used to avoid bias due to our small sample size.45 Each model was adjusted for group (PD-FoG 
versus PD+FoG), task (single versus dual-task), and the group*task interaction (to test whether 
groups had different linear trend between tasks). Each model included a random intercept for 
each participant to account for the repeated measurements within each participant. The 
association between PFC activity while walking (HbO2) and gait measures was explored, 
separately per group, using Spearman and Pearson correlation coefficients (according to data 
type and distribution). For PD+FoG, we also analyzed the association between PFC activity 
while walking and FoG severity (NFoGQ). The statistical analysis was conducted using Matlab 
R2019b (The Mathworks Inc., Natick, MA, USA) and SPSS v25 (IBM Inc., IBM Corp., 
Armonk, NY, USA). Statistical significance was set at p < 0.05. 
 
RESULTS 
Participant characteristics 
All demographic characteristics and clinical scale scores are reported in Table 1. There 
were no differences between groups for age, gender, height, weight, FAB, TMT_A, TMT_B-A, 
CLOX1 and CLOX2. PD+FoG had more severe motor symptoms (MDS-UPDRS-III) and 
advanced stage (H&Y), longer disease duration and worse cognition (MoCA and TMT_B) than 
PD-FoG.  
<Insert Table 1 here> 
 
PFC activity 
Freezers showed greater PFC activity than nonfreezers when controlling for severity of 
disease and cognitive status (i.e., MDS-UPDRS-III, H&Y, disease duration, MoCA and TMT-
B). Results of the two linear mixed-effects models for relative HbO2 and HHb are reported in 
Table 2. No significant results were observed for fNIRS outcomes in model #1, which did not 
control for covariates. While controlling for covariates (model #2), PD+FoG showed higher 
HbO2 in the late phase of walking compared to PD-FoG (p = 0.031; see Figure 1), regardless of 
walking condition. In addition, HbO2 and HHb, both in the early and late phases, were similar 
between single- and dual-task. Lastly, no significant group*task interactions were found in 
model #2.  
<Insert Table 2 and Figure 1 here> 
 
Gait 
Freezers and nonfreezers showed very similar gait characteristics, when results were 
controlled for severity of disease and cognitive status (i.e., MDS-UPDRS-III, H&Y, disease 
duration, MoCA and TMT-B). Results of the two linear mixed-effects models for spatiotemporal 
gait parameters are reported in Table 3. Model #1 revealed a group main effect for step time 
variability only (p = 0.044). PD+FoG showed greater step time variability than PD-FoG (Figure 
2). However, such difference was no longer significant in model #2, which revealed no 
significant group main effect (Table 3). Both models revealed task main effects for gait speed 
(model #1: p = 0.026; model #2: p = 0.029), stride length (model #1: p < 0.001; model #2: p < 
0.001) and foot strike angle (model #1: p = 0.012; model #2: p = 0.013). In fact, both groups had 
slower gait speed, shorter stride length and lower foot strike angle in the dual-task compared to 
single task (Figure 2). No significant group*task interactions were observed for gait outcomes.  
<Insert Table 3 and Figure 2 here> 
 
Concurrent cognitive task 
Freezers and nonfreezers showed similar performance on the cognitive dual task. Due to 
technical issues with the equipment (e.g., signals from button and inertial sensor not 
synchronized), the accuracy of the concurrent cognitive task was not evaluated in all participants. 
The accuracy is reported for 17 PD-FoG (mean ± standard error of the mean; seated: 0.91 ± 0.04; 
walking: 0.80 ± 0.07) and 15 PD+FoG (seated: 0.86 ± 0.07; walking: 0.79 ± 0.08). Both 
statistical models revealed no significant main effect or group*task interaction (p>0.05). 
 
Correlations 
During dual-task walking, greater HbO2 late was associated with less severe FoG (r = -
0.526, p = 0.011) and greater HbO2 early was associated with lower step time variability (r = -
0.463, p = 0.023) in PD+FoG; see Figure 3. For PD+FoG, no significant correlations were 
observed for HbO2 during single-task walking. No significant correlations were observed for PD-
FoG (p > 0.05). 
<Insert Figure 3 here> 
 
 
DISCUSSION 
To the best of our knowledge, this is the first study applying fNIRS to examine the 
influence of FoG status on PFC activity during single and dual-task walking in people with PD. 
To better isolate the influence of FoG status itself rather than disease progression, we controlled 
the analysis for between-group differences on demographic and clinical/cognitive variables. Our 
main results, when controlling for covariates, were: 1) PD+FoG had greater PFC activity while 
walking (i.e., higher HbO2 late levels) than PD-FoG, regardless of walking condition; 2) 
Spatiotemporal gait measures were similar in PD+FoG compared to PD-FoG, and both groups 
showed worse performance in dual-task compared to single-task; 3) higher PFC activity while 
walking was associated with less severe FoG and less variable gait, only in the PD+FoG group.  
These findings suggest that greater contribution of the executive locomotor network is required 
in PD+FoG due to impaired movement automaticity. Thus, our hypothesis of more pronounced 
reduction in automaticity of walking in PD+FoG was confirmed by PFC activity (measured by 
fNIRS) outcomes, but not by gait measures.  
 
NIR light illuminates reduction in automaticity of walking in freezers  
This study suggests that PFC activity, measured through mobile fNIRS, can identify 
reduction in automaticity of walking in PD+FoG. Overall, our findings corroborate previous 
studies showing that automaticity of walking is reduced in people with PD and even more in 
those with FoG.1,16 The observed deterioration of gait parameters under the dual-task condition 
in both groups suggests that walking is not an automatic task for people with PD,11,16 regardless 
of FoG status. Moreover, the increased PFC activity (HbO2 late level) observed in PD+FoG 
suggests further reduced automaticity of walking in this group, which is in line with existing 
fNIRS studies on turning.26,27 PD+FoG required the allocation of additional prefrontal executive 
resources for the control of walking, which is likely a compensatory mechanism to maintain gait 
performance comparable to non-freezers.  
In fact, in keeping with these findings, spatiotemporal gait parameters were unable to 
differentiate PD+FoG and PD-FoG, while controlling for covariates, even under the dual-task 
condition. Thus, fNIRS outcomes may be more sensitive than gait outcomes in identifying 
reduction in automaticity of walking in PD+FoG. Since PFC activation is argued to be part of a 
compensatory mechanism to maintain a certain level of task performance,22 it is also possible 
that changes in PFC activity precede further gait impairments in people with FoG. Such 
interpretation is supported by the literature. Changes in cortical activity have been proposed as a 
preclinical sign of (future) gait impairments and falls in healthy middle-aged adults46 and high-
functioning older adults.47 Longitudinal studies are needed to confirm (or not) if this line of 
interpretation applies to people with FoG.   
Although near-infrared light seems appropriate to illuminate reduction in movement 
automaticity in PD+FoG, careful definition of outcomes is required. The fact that between-group 
difference for HbO2 was only observed in the late phase of the task might relate to a sustained 
pattern of PFC activation throughout the task by PD+FoG. Several previous studies have 
reported PFC activation in the initial part of walking corresponding to gait initiation and 
acceleration phase.41-43,48 In healthy individuals, the initial increased PFC activity tend to be 
attenuated during later periods of walking, suggesting a more automatic control.41-43,48 On the 
hand, PFC activation has been shown to be sustained throughout the walking task in clinical 
populations, such as post-stroke patients.41 Thus, it is possible to interpret that PD+FoG had a 
more sustained PFC activation pattern throughout the task compared to PD-FoG. Alternatively, 
one may also speculate that a potential fatigability component of our task played a role. PD+FoG 
usually report increased perceived fatigue49 and, therefore, they are more susceptible to fatigue 
during a motor task. Fatigue negatively impacts performance in locomotor tasks50 and therefore 
may require more higher level attention to control locomotion. It is possible that PD+FoG 
increased PFC activity (relative to PD-FoG) to deal with the increasing fatigue level. Since this 
explanation is speculative, we encourage future studies designed (e.g., including fatigue 
outcomes or protocol to induce fatigue) to further explore the influence of fatigue on PFC 
activity in PD+FoG.  
 
Both groups prioritized the concurrent cognitive task 
Our findings demonstrated that while accuracy in the concurrent cognitive task was 
similar between seated and dual-task conditions for both groups, gait parameters deteriorated 
during dual-task walking. Thus, participants prioritized the concurrent cognitive task in 
detriment of gait performance, even not having received a specific instruction to do so. Such 
prioritization may have occurred due to a low hazard estimation by patients,51 as they were in a 
controlled environment and had a research assistant ensuring their safety. However, the adoption 
of the so called “posture-second” strategy may go at the expense of maintaining balance during 
daily activities in the real world.52 Since PFC activity was also similar between single and dual-
task walking, it is possible that participants allocated most of the available prefrontal cognitive 
resources for the performance of the cognitive task in the dual-task condition. As a consequence, 
gait deteriorated for not having the required level of prefrontal cognitive resources. 
 PFC activity during dual-task walking is associated with FoG severity and gait variability in 
PD+FoG  
In PD+FoG, we observed negative correlations between relative HbO2 during dual-task 
walking and NFoGQ score and step time variability. Specifically, freezers with greater PFC 
activity during dual-task walking had less severe FoG (perceived, self-reported) and lower step 
time variability. These findings suggest that those with less severe FoG may have more 
prefrontal resources available or a relatively more effective compensatory prefrontal executive 
control of gait (compared to those with more severe FoG). In addition, we observed no 
significant correlations involving PFC activity during single-task walking. This finding 
combined with the significant correlations involving PFC activity during dual-task walking 
reinforces the important role of the PFC in the control of locomotion during more demanding 
tasks.  
 
Clinical implications 
Findings suggest that PFC should be targeted for the development of enhanced 
interventions aiming to improve gait in PD+FoG. Cortical non-invasive brain stimulation offers a 
potential method to achieve this end.7 In fact, there is preliminary evidence that transcranial 
magnetic and direct current stimulation applied over the PFC improved turning53 and clinical 
symptoms of FoG.54  
 
Key study strength and limitation 
A key strength of this study is the robust data analysis methods for fNIRS processing, 
especially the use of short-separation channels to remove the superficial hemodynamic response 
from the fNIRS signal. This approach reduces the likelihood of false positive results55,56 and, 
therefore, is recommended.22,35 On the other hand, our study is limited by assessing the PFC 
only. Since PD leads to a broad cortical dysfunction,57 future studies should assess multiple 
cortical areas while walking for a more complete understanding of PD- and FoG-related cortical 
control mechanisms.     
 
CONCLUSION 
In conclusion, people with PD who report FoG have reduced automaticity of walking, 
based on PFC activity, in comparison to people without FoG, even when they have no actual 
FoG episodes. Higher PFC activity in people with FoG may be compensatory to maintain gait 
similar to people without FoG. PFC activity while walking seems to be more sensitive than 
spatiotemporal gait parameters in identifying changes in automaticity in people with PD who 
report FoG. 
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Table 1. Participants’ characteristics 
 
 
 
 
 
 
 
 
CLOX: Royall Clock Drawing Tasks; FAB: Frontal Assessment Battery; H&Y: Hoehn and Yahr Rating Scale; MDS-UPDRS: 
Movement Disorders Society - Unified Parkinson’s Disease Rating Scale; MoCA: Montreal Cognitive Assessment; NFoGQ: 
New Freezing of Gait Questionnaire; PD-FoG: people with Parkinson’s disease without freezing of gait; PD+FoG: people with 
Parkinson’s disease with freezing of gait; TMT: Trail Making Test. 
 
 
  
Variable PD-FoG PD+FoG pValue 
NFoGQ 0 ± 0 12.2 ± 5.8 <0.001 
Gender (male / female) 18 / 5 16 / 8 0.380 
MDS-UPDRS-III (score) 35.0 ± 10.3 42.4 ± 13.2 0.038* 
H&Y (I / II / III) 1 / 19 / 3 0 / 16 / 8 0.09t 
Disease duration (years) 7.2 ± 5.2 10.1 ± 6.1 0.072t 
MoCA (score) 27.2 ± 3.7 26.0 ± 3.1 0.020* 
FAB (score) 14.6 ± 3.1 14.6 ± 3.0 0.940 
TMT_A (s) 36.5 ± 15.6 51.9 ± 57.7 0.395 
TMT_B (s) 83.5 ± 38.5 116.5 ± 56.1 0.035* 
TMT B-A (s) 46.9 ± 30.4 64.5 ± 44.9 0.125 
CLOX1 (score) 12.1 ± 2.0 12.2 ± 1.4 0.761 
CLOX2 (score) 13.9 ± 0.9 13.3 ± 1.6 0.208 
Age (years) 70.8 ± 7.6 70.3 ± 4.7 0.756 
Height (cm) 169.6 ± 12.8 167.9 ± 13.2 0.461 
Weight (kg) 84.4 ± 21.9 78.8 ± 14.8 0.580 
Table 2. Results of the statistical models applied for fNIRS outcomes, while controlling (model #2) or not 
(model #1) for covariates, which included MDS-UPDRS-III, H&Y stage, disease duration, MoCA and 
TMT-B.  
 
Variable Estimate SE pValue Lower 95% CI Upper 95% CI 
Model 1       
Group effects      
HbO2 early -0.078 0.108 0.472 -0.294 0.137 
HHb early 0.060 0.060 0.321 -0.059 0.179 
HbO2 late -0.239 0.140 0.092 -0.518 0.040 
HHb late 0.116 0.082 0.157 -0.046 0.279 
      
Task effects      
HbO2 early -0.108 0.094 0.251 -0.294 0.078 
HHb early 0.064 0.048 0.185 -0.031 0.160 
HbO2 late -0.143 0.114 0.215 -0.370 0.084 
HHb late 0.100 0.064 0.125 -0.028 0.228 
      
Group*task      
HbO2 early 0.054 0.059 0.364 -0.064 0.173 
HHb early -0.035 0.031 0.258 -0.096 0.026 
HbO2 late 0.082 0.073 0.259 -0.062 0.227 
HHb late -0.045 0.041 0.275 -0.127 0.036 
      
Model 2      
Group effects      
HbO2 early -0.107 0.111 0.338 -0.328 0.114 
HHb early 0.073 0.062 0.243 -0.051 0.197 
HbO2 late -0.314 0.143 0.031 -0.598 -0.029 
HHb late 0.146 0.084 0.086 -0.021 0.314 
      
Task effects      
HbO2 early -0.105 0.094 0.269 -0.292 0.082 
HHb early 0.063 0.048 0.195 -0.033 0.159 
HbO2 late -0.135 0.115 0.242 -0.598 -0.029 
HHb late 0.097 0.064 0.137 -0.031 0.225 
      
Group*task      
HbO2 early 0.053 0.06 0.381 -0.066 0.172 
HHb early -0.034 0.031 0.267 -0.095 0.027 
HbO2 late 0.079 0.073 0.283 -0.066 0.225 
HHb late 0.044 0.041 0.291 -0.125 0.038 
CI: confidence interval; HbO2: oxygenated hemoglobin; HHb: deoxygenated hemoglobin; SE: standard error. 
 
 
 
 
  
Table 3. Results of the statistical models applied for gait outcomes, while controlling (model #2) or not 
(model #1) for covariates, which included MDS-UPDRS-III, H&Y stage, disease duration, MoCA and 
TMT-B.  
 
Variable Estimate SE pValue Lower 95% CI Upper 95% CI 
Model 1      
Group effects      
Speed 0.011 0.062 0.862 -0.112 0.133 
Foot strike angle -0.330 1.568 0.833 -3.447 2.785 
Stride length 0.039 0.057 0.498 -0.075 0.154 
Step time variability -1.609 0.787 0.044 -3.173 -0.045 
      
Task effects      
Speed -0.063 0.028 0.026 -0.119 -0.008 
Foot strike angle -1.553 0.609 0.012 -2.764 -0.343 
Stride length -0.077 0.021 <0.001 -0.119 -0.034 
Step time variability -0.394 0.455 0.389 -1.298 0.510 
      
Group*task      
Speed 0.014 0.018 0.436 -0.021 0.049 
Foot strike angle 0.250 0.388 0.521 -0.521 1.021 
Stride length 0.019 0.014 0.173 -0.008 0.046 
Step time variability 0.401 0.290 0.170 -0.174 0.976 
      
Model 2      
Group effects      
Speed -0.075 0.055 0.173 -0.183 0.034 
Foot strike angle -1.434 1.622 0.379 -4.66 1.792 
Stride length -0.044 0.049 0.368 -0.141 0.053 
Step time variability -0.803 0.722 0.269 -2.238 0.632 
      
Task effects      
Speed -0.062 0.028 0.029 -0.118 -0.007 
Foot strike angle -1.548 0.612 0.013 -2.764 -0.332 
Stride length -0.075 0.021 <0.001 -0.118 -0.033 
Step time variability -0.392 0.455 0.391 -1.300 0.513 
      
Group*task      
Speed 0.013 0.018 0.452 -0.022 0.049 
Foot strike angle 0.247 0.389 0.527 -0.526 1.020 
Stride length 0.018 0.014 0.191 -0.009 0.045 
Step time variability 0.400 0.290 0.170 -0.176 0.977 
CI: confidence interval; SE: standard error. 
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